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Retinoblastoma protein (Rb) interacts with cyclin-
dependent kinases and regulates the transcription of
genes necessary for progression through the S phase of
the cell cycle. Clues to the atomic mechanisms involved
are offered by the structure of the two pocket regions of
Rb in complex with a short peptide from a viral
oncoprotein. Structures of cyclins, Rb and TFIIB reveal that
a common motif occurs in proteins regulating three
consecutive events of cell-cycle control.
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Introduction
The Rb gene was cloned and characterised through the
correlation of genetic lesions at its locus with the develop-
ment of retinal tumours in children [1–3]. Since then it has
been shown that the genomes of cells from a wide variety
of tumour types, notably small-cell lung cancer, osteo-
sarcomas and bladder carcinomas, contain mutations that
inactivate Rb [4]. In the cells of many other types of
tumours, Rb function is compromised through mutations
in molecules that regulate Rb activity such as cyclin D
and the cyclin-dependent kinase (CDK) inhibitor p16
(reviewed in [5]). Together, this evidence has identified
Rb as a tumour suppressor, able to inhibit cell division
through its unique position at the molecular interchange
between the processes that coordinate cell-cycle progres-
sion and the downstream events that initiate the transcrip-
tion of genes required for the G1→S transition and DNA
replication. The region of Rb required for growth inhibi-
tion includes two regions conserved between Rb family
members, together termed the A–B pocket. Following on
from the determination last year of the structure of the Rb
A pocket region by Kim and Cho [6], Lee et al. have now
described the structure of this A–B pocket in complex
with a peptide ligand [7].
The role of Rb
Rb negatively regulates cell-cycle progression largely by
repressing the activity of the transcription factor E2F [5].
Elevation of E2F activity has been shown to be suffi-
cient to drive quiescent cells into S phase [8]. Binding of
hypophosphorylated Rb to E2F down regulates its trans-
activation activity and, at certain promoter sequences,
Rb and E2F can form a complex that actively represses
transcription [9]. E2F transcription factors are hetero-
dimers composed of an E2F subunit and a DP subunit.
Five E2F and two DP family members have been identi-
fied (reviewed in [10]). Rb characteristically, but not
exclusively, associates with E2Fs containing the E2F-1,
-2 or -3 subunits, whereas the Rb-related proteins p107
and p130 preferentially associate with E2F-4 and E2F-5
(reviewed in [5,11]). Active E2F is released following
hyperphosphorylation of Rb by members of the CDK
family. There are sixteen CDK consensus phosphoryla-
tion sites in Rb and early mapping experiments sug-
gested that many of them are functional in vivo [12–14]
(Figure 1). Cyclin D1-CDK4 and cyclin A/E-CDK2 phos-
phorylate different Rb sites in vivo [15,16]. Distinct
subsets of Rb phosphorylation sites modulate Rb binding
to E2F, to LXCXE motif-containing proteins and to
c-Abl [16,17]; reviewed in [18].
The minimal Rb sequence required for its growth sup-
pression activities has been mapped to the C-terminal
region of the protein (residues 395–876). This sequence
contains three distinct protein-binding sites, through
which it associates with a number of proteins in addition
to E2F [19]. The A–B pocket consists of two distinct
sequences that are conserved between pocket-protein
family members, p107, p130 and Rb. The pocket region
of Rb in isolation is able to bind oncoproteins of a
number of DNA tumour viruses, notably E1A from
adenovirus, the large T antigen from SV40 and E7 from
human papillomavirus (HPV) [20]. These proteins contain a
characteristic LXCXE motif. The same motif is found in
a number of other proteins, many of which are transcrip-
tion factors that are able to bind to the A–B pocket
region of Rb [14]. 
Although E2F does not have the LXCXE motif, binding
of E2F to Rb requires the A–B pocket region, as well
as additional residues towards the C terminus of the C
domain (sometimes collectively referred to as the large
pocket). The C domain also forms a binding site for
c-Abl tyrosine kinase and the transcription factor Mdm2
[21,22]. Rb can simultaneously bind various combina-
tions of these proteins, an observation which provides
part of the evidence for the current model of Rb’s func-
tion as a ‘molecular matchmaker’ in the assembly of macro-
molecular complexes [19].
The ability of Rb to bind to multiple transcription factors
may in part explain its function as a specific repressor of
certain genes that are transcribed by polymerase II (pol II)
and are not E2F-dependent. Rb is also able to repress
transcription from both pol I- and pol III-dependent pro-
moters [23]. Pol I synthesizes large ribosomal RNAs
(rRNA) and pol III transcribes genes encoding a variety of
small stable RNAs, including 5S rRNA and tRNAs, all of
which are essential for cell growth. An attractive hypothe-
sis, therefore, is that by inhibiting pol I and pol III activity
Rb may be able to complement its activity as an inhibitor
of the chromosome cycle with an ability to put the brakes
on cell growth [23].
Structural context
Structural characterisation of cell-cycle proteins to date
has focussed on the CDKs. These molecules are regu-
lated by both phosphorylation and non-covalent associa-
tion with regulatory partners. Crystal structures have illus-
trated various complexed states of one CDK, CDK2
[24–26]. These structures, together with the structures of
the isolated cyclin and CDK components [27,28], suggest
that the CDKs are rather plastic molecules, the conforma-
tion of which can be altered to affect their activity by the
binding of either positive or negative regulatory partners
(e.g. cyclin and p27, respectively), as well as by phos-
phorylation. Only once appropriately phosphorylated and
complexed with a cyclin partner, does a CDK adopt its
fully catalytically competent conformation. This confor-
mation can be comprehensively disrupted by the binding
of a proteinaceous inhibitor molecule, such as a p27. The
work of Lee et al. [7] extends the range of cell-cycle regu-
latory processes for which structural information is avail-
able downstream from the regulation of CDKs, and into
the domain of crucial substrates through which CDKs
exert their effect. Here, a structural echo of the CDK reg-
ulatory events is observed, as Rb contains two copies of
the structural motif found in the cyclin molecule.
The cyclin-box fold connection
As suggested from profile-based sequence analysis [29],
and subsequently supported by a threading study [28],
the B-pocket region of Rb shares the cyclin-box fold
(CBF) that is found in cyclins [28,30,31], transcription
factors of the TFIIB family [32] and the A-pocket region
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Table 1
Sequence and structural similarity of different cyclin-box folds*.
Cyclin A Cyclin H TFIIB Rb
N C N C N C N C
Cyclin A
N – 2.04 1.64 1.99 1.36 1.52 2.44 2.25
C 11.11 – 1.90 1.83 1.87 1.61 2.04 2.03
Cyclin H
N 18.81 12.87 – 2.28 1.71 2.27 2.22 2.55
C 9.9 10.89 11.88 – 2.17 2.03 2.39 2.52
TFIIB
N 14.14 7.45 13.86 6.93 – 1.07 1.89 1.57
C 12.12 10.64 9.9 8.91 20.21 – 1.83 1.65
Rb
N 8.33 7.41 4.63 6.48 9.26 6.48 – 2.27
C 7.89 6.14 11.4 7.02 14.91 8.77 5.26 –
*The structures of the eight different cyclin-box folds (CBFs) were
aligned automatically using the program STAMP, and equivalent
residues compared. For each pairwise comparison, this table
presents the root mean square deviation for equivalent Cα positions
(top right), and the percentage sequence identity for equivalent
residues (bottom left).
Figure 1
Summary of the binding functions and
phosphorylation sites in Rb [19]. The A-, B- and
C-pocket regions of Rb are marked. The
mapped binding sites for the LXCXE motif, E2F
and the c-Abl tyrosine kinase are indicated with
bars. The nuclear localisation signal (NLS) and
the DEADG motif are also shown. Serine (249,
567, 608, 612, 780, 788, 795, 807 and 811)
and threonine (5, 280, 252, 356, 373, 821 and
826) phosphorylation sites are marked
schematically with lines (red and green,
respectively).
1 393
395
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Structure
of Rb [6]. The CBF consists of approximately 100 amino
acids which form a bundle of five helices. A structural
alignment of the eight available cyclin-box folds (two in
each of cyclin A, cyclin H, TFIIB and Rb) reveals
sequence identity which varies between five and twenty
percent (Table 1). The structural similarity encoded by
this sequence identity is surprisingly high, with pairwise
comparisons yielding root mean square deviations (rmsds)
of between 1.1 Å and 2.5 Å for equivalent Cα positions.
Few obvious patterns which might direct adoption of the
CBF are apparent from sequence comparisons. Even the
previously noted run of four small non-polar amino acids
[29] along the buried helix (α3) do not survive the addi-
tion of the B-box of Rb to the alignment (Figure 2).
The CBF as a tandemly duplicated motif
Different CBFs are elaborated in different ways by excur-
sions from and extensions to the basic architecture. Con-
firmation that the B-pocket region of Rb forms a CBF
means that in all of the characterised cases, the CBF is
found tandemly repeated. Despite this, the relative dispo-
sition of the two repeats differs markedly in the different
classes of protein (Figure 3), and whether an isolated CBF
exists in nature remains open to debate. The strongest
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Structure
Sequence alignment of cyclin-box fold (CBF) proteins. CBFs were automatically structurally aligned with the program STAMP [43], and the
corresponding sequence alignment was illustrated using ALSCRIPT [44]. Boxed regions correspond to areas of structural equivalence.
suggestion for such an entity comes from the p35 reg-
ulatory subunit of CDK5 [33]. No sequence analysis has
been able to detect more than a single CBF in the p35
sequence [28], and a 25 kDa fragment of p35 is active in
promoting CDK5 activity, despite being scarcely long
enough to encode two CBFs [34].
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Figure 3
Theme and variation: the CBFs in (a) TFIIB, (b) Rb and (c) cyclin A. In
each CBF, residues corresponding to the CBFs are colour-ramped
from blue (N-terminal end) to red (C-terminal end). Elaborations of the
CBF core are coloured grey. The N and C termini of the proteins are
indicated. The N-terminal CBF is marked CBF1 and the C-terminal
CBF is marked CBF2. The views are chosen so that the N-terminal
CBF of each protein (CBF1) is drawn in the same orientation. From
this view, it is apparent that all three proteins have very different
relative orientations of the N- and C-terminal CBFs.
Figure 4
Surfaces of the common interaction site in (a) TFIIB, (b) Rb and (c)
cyclin A. The molecular surface of each protein is shown in gold, with
the interacting molecule shown in ball-and-stick representation. Each
interacting CBF is drawn in the same relative orientation. For Rb, the
interacting LXCXE-motif peptide is shown. For cyclin A, the fold of the
interacting CDK2 molecule is shown, together with explicit bond
representation for residues interacting with this site. For TFIIB, the fold
of TBP is shown with explicit bond representation of the interacting
residues. TFIIB drawn in this orientation has the C-terminal CBF coming
towards the point of view, so that it is clipped by a viewing plane.
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In cyclin A, it is the N-terminal CBF that mediates the so
far characterised protein–protein interactions: association
with CDK2 and with the inhibitor p27 [24,26]. p27 binds
through a conserved sequence motif (RXLFG), found in
other members of the p21 CDK-inhibitor (CKI) family, the
N-terminal sequences of E2F-1, -2 and -3, and in the p107
linker sequence [35]. In TFIIB, both N-terminal and C-ter-
minal CBFs mediate interactions with DNA and the
TATA-binding protein (TBP) [32]. Lee et al. have charac-
terised the site of Rb for one important class of interaction:
that with proteins which contain the LXCXE motif. A nine-
residue peptide derived from the E7 protein of human
papilloma virus binds to the B-pocket of Rb. Lee et al. pos-
tulate that the function of the A-pocket region is to stabilise
the fold of the B-pocket region, with which it shares a con-
tinuous hydrophobic core. They also note that the A–B
interface may be a site of protein–protein interaction. 
Interaction sites in CBF proteins
Lee et al. observe that sequence conservation and the
sites of loss-of-function mutations are concentrated in two
regions of Rb: one on the B-pocket region and one at the
A/B pocket interface. The former of these two regions is
responsible for the binding of the E7 peptide, containing
the LXCXE motif. The pattern of alternating conserva-
tion and degeneracy across the LXCXE motif is neatly
explained by the extended conformation of the bound
peptide, so that peptide sidechains point alternately into
and away from the binding site. The binding site itself is a
groove in the protein surface composed of helices corre-
sponding to the last three structural helices of the B-pocket
region CBF. Rb is not alone in using this part of the CBF
for protein–protein interactions — it is the same as the
shared protein-interaction site identified in TFIIB and
cyclin A [36]. In the N-terminal CBF of cyclin A, this
groove interacts with the N-terminal loop preceding the
PSTAIRE helix of CDK2 [24], whereas in TFIIB, it
interacts with the stirrup part of the TBP [32]. Analysis of
the surfaces mediating these interactions (Figure 4) shows
that Rb has a narrow groove, with occasional deep and
hydrophobic wells appropriate to receive residues of the
extended LXCXE peptide. In the case of cyclin A, a wider
groove accommodates the N-terminal end of the C-helix of
CDK2, whereas the preceding loop meanders over the
surface of the cyclin molecule. The equivalent groove of
TBP is continuous with the cleft separating the N-terminal
and C-terminal CBFs, and TPB interacts via residues from
both domains. This conserved interaction site contrasts
with the p27 RXLFG-recognition site on the N-terminal
CBF of cyclin A. In the other CBFs, this site is either inac-
cessible or unoccupied.
A recently developed protocol (MEMN, unpublished data)
for evaluating a hydrophobic potential at a molecular
surface has been used to analyse the surface of Rb. This
protocol is based on a combination of the GRID algorithm
[37] and the Connolly Molecular Surface Package [38]. It
has been found in other cases to identify sites of apolar
protein–protein interaction, such as the interaction between
SH3 and its polyproline ligand, or the LFG motif of p27
with cyclin A. As can be seen in Figure 5, this analysis
highlights the hydrophobic pockets of Rb responsible for
binding the apolar subsites of the E7 peptide. It also illumi-
nates a patch on the A-pocket region, formed from the
interface between α1, α3 and α5. This site is a candidate
for some of the additional interactions of Rb, either inter-
molecular interactions with other proteins or intramolecular
interactions with other regions of the Rb protein.
Outstanding questions
Pocket proteins are not only substrates for members of
the CDK family, they can also form stable complexes.
Figure 5
Hydrophobic potential analysis of Rb. The molecular surface of the
molecule is coloured according to the GRID hydrophobic potential. A
strong preference for a hydrophobic group is indicated by a yellow
colour, and no preference for a hydrophobic interaction is indicated by
blue colouring. The E7 peptide is shown, interacting with the
hydrophobic wells on the B-pocket region (upper). An exposed
hydrophobic patch is offered by the A-pocket region (lower).
Rb binds to members of the cyclin D family, an inter-
action that requires the cyclin D LXCXE motif present
near its N terminus [39]. The formation of a stable
p107–CDK2–cyclin A complex requires the RXLFG
sequence motif found in the linker region of p107 [40].
This result suggests that p107 (and E2F-1, -2 and -3)
might employ similar structural tactics to those of p27 to
bind to certain members of the cyclin family. In addition,
the results described by Lee et al. show that E2F-1, -2
and -3 can also bind directly to the CBFs of Rb through a
second motif, conserved amongst all E2F family
members. Binding of p21, and p107 or p130 to
CDK2–cyclin complexes, is mutually exclusive [41],
although this need not imply similarity in binding mode
beyond the RXLFG motif. The crystal structure of a
ternary complex formed between CDK2, cyclin A and
p27 has revealed that p27 goes on to inhibit CDK2 in a
tour de force of molecular disruption, whereas the CDK2
associated with p107 (and E2F-1, -2 or -3) can remain
catalytically active [42]. 
The CBF provides a common structural theme, linking
CDK regulation, the control of transcription initiation
and the basal transcription machinery. Lee et al. have
shown details of the interactions between Rb and the
LXCXE binding motif, confirming that CBFs use a
common set of interaction sites to carry out their func-
tions. The outstanding structural question is how the
library of interactions available is used to appropriately
assemble and regulate the macromolecular complexes
that govern cell-cycle progression.
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